

# TRASPLANTE RENAL

*Dra. Vanesa Pomeranz*

*Abril 2014*


# INMUNOLOGÍA DEL TX

- Relación entre los tejidos:
  - Singénica: gemelos idénticos
  - Allogeneneica: misma especie
  - Xenogeneica: distinta especie


# RESPUESTA INMUNE

- Se inicia por activación de CPA a través del sistema inmune innato
- Cél dendríticas del donante y R se activan y migran a órganos linfoides, con activación de linf T naive de memoria, que a su vez activan linf B y producen auto Ac contra HLA del donante
- Activación T: modelo de 3 señales
  - Ca-calcineurina
  - Proteinkinasa (MAP kinasa)
  - NF kb
- Linf T activado: expresa IL-2, CD 154, CD 25 (R IL-2).
  - Prolifera y se diferencia a linf T efector  **rechazo**

## Generation of Alloimmune Responses




# MODELO DE LAS 3 SEÑALES



# RECHAZO

- Injuria tisular por rta adaptativa alloinmune
  - Deterioro de Fx del injerto
  - 2 tipos: mediado por células T y mediado por Ac
  - Infiltrado: células T, B, macrófagos, plamocitos
  - Linfocitos T:
    - CD4 : interactúan con CMH II
    - CD8+: CMH I
  - El injerto induce rta alloinmune por Ag no propios reconocidos por linf T del R, a través de 2 vías de reconocimiento: indirecta (CPA del R) y directa (CPA del donante)

- CMH: HLA
  - 3 clases
    - I: A, B, C
    - II: DR, DQ, DP
    - III
  - Rechazo: A, B, DR
  - Herencia: 1 haplotipo



# EVALUACIÓN PRE TX

## Contraindications to Renal Transplantation

Current Absolute Contraindications to Transplantation	Previous Contraindications to Transplantation (now acceptable under certain circumstances – see text)
<ul style="list-style-type: none"><li>• Active Sepsis</li><li>• Current uncontrolled malignant disease</li><li>• Uncontrolled psychosis</li><li>• Active drug dependence</li><li>• Any medical condition with a severely shortened life expectancy (&lt;1–2 years)</li><li>• Positive T-cell CDC cross match</li></ul>	<ul style="list-style-type: none"><li>• HIV Infection</li><li>• Hepatitis B and C</li><li>• Obesity</li><li>• Mood disorders</li><li>• Age &gt; 60 years</li><li>• Previous malignant disease</li><li>• Blood group incompatibility</li></ul>

# Recipient Evaluation Checklist

## History and Examination

Cause of renal failure and risk of recurrence  
Sensitization (transfusion, pregnancy, previous transplant)  
Past and current infections (TB, hepatitis, HIV)  
Immunization (especially hepatitis B)  
Malignancy  
Cardiovascular risks (smoking, hypertension, diabetes)  
Pulmonary, gastrointestinal disease  
Genitourinary tract  
Psychiatric, psychological history  
Surgical issues (weight, iliac vessels, abdomen, previous surgery)

## Laboratory and Radiologic Investigations

Viral serology (HIV, CMV, EBV, hepatitis B and C)  
Liver function tests  
Bone-related issues (PTH, calcium, phosphate)  
Chest radiograph  
Electrocardiogram  
Prostate-specific antigen (for men >50-60 years old)  
Mammogram or breast ultrasound  
(women >50 years old or with family history of breast cancer)  
Pap smear (sexually active women)

## Immunologic Investigations

ABO blood group and HLA typing  
Screening for HLA antibodies and autoreactive antibodies  
Crossmatching


- **DONANTES:**

- Vivos: relacionados o no
- Fallecidos
  - Corazón paciente
  - Corazón parado
  - Criterios expandidos
- Compatibilidad:
  - ABO
  - No importa el Rh
  - ABO incompatibles? Previa desensibilización
  - Mismach HLA: a > compatibilidad, > sobrevida del injerto
  - Crossmatch:
    - Citotoxicidad
    - Citometría de flujo: más sensible
    - Luminex: Ac anti donante

Live Donor Evaluation Checklist: History and Examination	
History	
Hypertension	
Diabetes (including gestational)	
Infections	
Cancer (including skin lesions)	
Vascular disease	
Renal calculi	
Gout	
Urinary tract	
Family history	
Medications (including NSAIDs, herbs)	
Smoking	
Elicit and intravenous drug use	
Sexual history	
Vocation, sport interests	
Level of physical activity/exercise	
Psychiatric history/psychological factors	
Willingness to donate	
Relationship with recipient	
Examination	
Blood pressure	
Weight and height, BMI	
Joints, skin	
Cancer (including skin lesions, breast)	
Lymph nodes	
Vascular disease	
Heart and lungs	
Abdomen	

Live Donor Evaluation Checklist: Investigations	
Laboratory and Radiologic Investigations	
Urinalysis (blood, protein)	
Urine microscopy and culture (blood, organisms)	
Serum electrolytes, urea and creatinine	
Liver function tests	
Full blood examination	
Fasting blood glucose and/or oral glucose tolerance test	
Fasting lipids	
24-hour urine, creatinine clearance, protein excretion (or GFR measurement by other methods, [e.g., iothalamate clearance, nuclear GFR by Cr-EDTA, DTPA; protein excretion by other methods], [e.g., protein-creatinine ratio])	
Serum uric acid, calcium, phosphate	
Viral screening: HBV, HCV, HIV, CMV, EBV serology	
Syphilis screening (RPR)	
TB screening (PPD)	
Electrocardiogram	
Chest radiograph	
Females: Pap smear, mammography (according to age/family history)	
Males: prostate-specific antigen (according to age/family history)	
Additional cardiac investigations (where indicated by age/history/risk factors)	
Stress test	
Echocardiography	
Ambulatory blood pressure	
Renal Anatomy (as per local expertise)	
Computed tomographic angiography	
Magnetic resonance imaging angiography	
Catheter angiography	

## Survival of Kidney Donors and Controls from the General Population



# INMUNOSUPRESIÓN

- 2 etapas:
  - Inducción
  - Mantenimiento
- **Corticoides:**
  - VO: prednisona, prednisolona
  - EV: metilprednisolona
  - Antiinflamatorios e IS
  - Mantenimiento y rechazo agudo
  - Seguros en embarazo

- **CIN:**
  - Ciclosporina, tacrolimus
  - Inhiben calcineurina (activación linf T)
  - Nefrotóxicos reversible (VC) e irreversible (hialinosis arteriolar y fibrosis intersticial)
  - Inducción y mantenimiento
  - Control con niveles plasmáticos
  - Útiles en embarazo



- **Azatioprina:**
  - Antimetabolito análogo de purinas
  - Mantenimiento

- **Micofenolato:**
  - Mofetil y sódico
  - Inducción y mantenimiento
  - No en embarazo
- **M-tor:**
  - Sirolimus y everolimus
  - Mantenimiento
- **Anticuerpos:**
  - Monoclonales:
    - Anti CD25: Basiliximab, Daclizumab → Inducción
    - Anti CD 20: Rituximab → Rechazo mediado por Ac y desensibilización
    - Belatacept → Mantenimiento
  - Policlonales: tímoglobulina → Inducción y tto del rechazo corticoR
  - IVIG → Rechazo humoral, desensibilización

Common Side Effects of Small Molecule Immunosuppressive Medications							
	Cyclosporine	Tacrolimus	Mycophenolate	Azathioprine	Corticosteroids	mTOR Inhibitors	Leflunomide
Renal	Nephrotoxicity, type IV RTA, HTN, diuretic resistance, hyperkalemia, hypomagnesemia, hypophosphatemia	Nephrotoxicity, type IV RTA, HTN, diuretic resistance, hyperkalemia, hypomagnesemia, hypophosphatemia			HTN, hypokalemia, diuretic resistance	Synergistic nephrotoxicity with CNIs, delayed recovery from ATN, proteinuria, hypokalemia, HTN	
Gastrointestinal		Diarrhea, abdominal pain	Diarrhea, nausea and vomiting, gastitis, esophagitis, oral and colonic ulcers	Nausea and vomiting, hepatotoxicity, pancreatitis	Peptic ulcers, gastitis, esophagitis, diarrhea, colonic perforation	Diarrhea	Nausea, diarrhea, hepatitis
Hematologic	Thrombotic microangiopathy	Thrombotic microangiopathy	Anemia, leukopenia, thrombocytopenia	Anemia, leukopenia, thrombocytopenia	Leukocytosis, polycythemia	Thrombotic microangiopathy, anemia, thrombocytopenia	Anemia, leukopenia
Metabolic	Hyperlipidemia, hyperuricemia, gout, glucose intolerance	New onset diabetes			Hyperlipidemia, hyperuricemia, hyperglycemia, osteoporosis, vascular necrosis, increased appetite and weight gain	Hyperlipidemia	
Cosmetic	Gingival hyperplasia, coarsened facial features	Alopecia			Hirsutism, acne, cushingoid facies, buffalo hump	Impaired wound healing, oral ulcers	Alopecia
Neuromuscular	Encephalopathy, insomnia, myopathy, tremors	Encephalopathy, insomnia, myopathy, tremors			Psychosis, insomnia, myopathy	Reflex sympathetic dystrophy	
Other	Edema	Myocardial hypertrophy	Viral infections, pulmonary edema in elderly, progressive multifocal leukoencephalopathy		Cataracts	Lymphocele, interstitial pneumonitis, rash, edema	Rash

# CIRUGÍA

- Heterotópico en fosa ilíaca contralateral
- Anastomosis venosa con ilíaca externa
- Anastomosis arterial con ilíaca interna o externa
- Anastomosis uréter con vejiga
- Colocación de catéter doble J




# Complicaciones Cx

- Infección de la herida
- Sangrado de la herida
- Vasculares:
  - Sangrado del hilio
  - Hemorragia de la anastomosis
  - Trombosis arterial
  - Trombosis venosa
  - Estenosis arteria renal
- Linfocele
- Urológicas:
  - Leaks
  - Obstrucción
- Lesión nerviosa
  - Fémorocutáneo
  - Obturador
  - Sacro
- Lesión arteria testicular


# RECHAZO

- TARGET: CMH del donante
- Factores de riesgo:
  - DGF (edad del donante y R, sensibilización, tiempo de isquemia)
  - Afroamericanos
  - < añosos
  - Sensibilización, esp ABO
  - IS: < policlonales, > sin corticoides, > si demora en CIN
- Clínica: AKI. Raro fiebre, dolor, oliguria
- Dx: Eco + Doppler (aumento IR). **BIOPSIA**

# Tipos de rechazo



Classification of Rejection	
Antibody Mediated	
<i>Acute</i>	C4d+, presence of circulating antidonor antibodies and acute tissue injury I. ATN-like (minimal inflammation) II. Capillary and/or glomerular inflammation and/or thromboses III. Arterial inflammation
<i>Chronic</i>	C4d+, presence of circulating antidonor antibodies and chronic tissue injury (1) Glomerular double contours, (2) peritubular capillary basement membrane multilayering, (3) tubular atrophy/interstitial fibrosis, and/or (4) fibrous intimal thickening in arteries
T Cell Mediated	
<i>Acute</i>	Mononuclear cell interstitial inflammation and tubulitis and/or arteritis IA: >25% Interstitial infiltration, 4–10 mononuclear cells/tubular cross section IB: >25% Interstitial infiltration, >10 mononuclear cells/tubular cross section IIA: Intimal arteritis, mild to moderate (0%–25% of luminal area) IIB: Intimal arteritis, severe (>25% of luminal area) III: Transmural arteritis and/or fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocyte inflammation
<i>Chronic</i>	Arterial intimal fibrosis with mononuclear cell infiltration in fibrosis, formation of neointima
<i>Borderline</i>	10%–25% Interstitial infiltration, <4 mononuclear cells/tubular cross section



- Tratamiento:
  - Agudo celular: corticoides, timoglobulina
  - Mediado por Ac: remover Ac (optimizar IS, PF, IVIG, timoglobulina, Rituximab)
  - Profilaxis: CMV, PCP
- Dx dif: nefropatía por virus BK

# Complicaciones médicas

- HTA:
  - CIN, corticoides
  - Imp causa de muerte con injerto funcionante la CV
  - No estudios con antiHTA
- DBT:
  - Asociación con HVC
  - Tacrolimus, corticoides
- DLP:
  - Ciclosporina, corticoides, FK, sirolimus
- Obesidad

# Infecciones

- 1er mes:
  - Bacterias nosocomiales, Candida, HSV
- 1-6 meses:
  - Virus: **CMV**, HSV, HZV, EBV, HBV, HCV
  - Hongos y oportunistas (PC, Listeria, Aspergillus, Nocardia, Toxoplasmosis)
- > 6 meses: similar a población general, salvo pac con rechazo
- **Virus BK:** viruria, viremia, estenosis ureteral, NTI, nefropatía, rechazo. Imp screening

# Malignidad

- Riesgo según IS
- Virus: papiloma y CA cuello uterino, EBV  
PTLD, HVB-HVC CA hepatocelular, HV8  
Kaposi
- Recurrencia de MM, piel no melanoma,  
vejiga, sarcomas, células claras, mama
- Más común: neoplasias de piel, luego  
PTLD



# Nefropatía crónica del injerto

- Causa + frec de disfunción crónica del injerto
- AP: FIAT, glomeruloesclerosis, engrosamiento miointimal
- Factores de riesgo: rechazo agudo, C4d+, missmatch, CMV, Tx previos, jóvenes, toxicidad CIN, cadavéricos, DGF, tipo de donante, HTA, DLP, TBQ, proteinuria
- Dx: HTA, IRC, proteinuria. Bx renal

# Trasplante de páncreas

- DBT IR con complicaciones (nefropatía, retinopatía, neuropatía)
- DBT con hipoglucemia inadvertida
- Rol no claro en DBT tipo II
- < 48 años (< 55?)
- Primer Tx, no sensibilizados, isquemia < 12 hs
- Tx doble o páncreas dps de riñón

## Pancreatic Transplant with Bladder Drainage



# Evolución

- Mejor control metabólico
- Retinopatía variable
- Mejoría de neuropatía
- Mejor control de HTA y menor progresión de enfermedad macrovascular